

Literatura ACTA MEDICINAE 12/2019 Vnitřní lékařství

- 3 **Kombinační léčba hypertenze**
prof. MUDr. Miroslav Souček, CSc. II. interní klinika a ICRC FN u sv. Anny v Brně a LF MU, Brno
- 3 **Moderní léčba fibrilace síní**
prof. MUDr. Josef Kautzner, CSc., FESC Klinika kardiologie, Institut klinické a experimentální medicíny, Praha
- 4 **Postavení betablokátorů v léčbě srdečního selhání**
doc. MUDr. Vilém Danzig, Ph.D., FESC II. interní klinika VFN a 1. LF UK, Praha
- 4 **Kombinovaná léčba dyslipidemií**
doc. MUDr. David Karásek, Ph.D. III. interní klinika – nefrologická, revmatologická a endokrinologická, FN Olomouc a LF UP, Olomouc
- 5 **Postavení enoxaparinu ve spektru současných antikoagulancií**
prof. MUDr. Jan Bultas, CSc. Farmakologický ústav, 3. LF UK, Praha
doc. MUDr. Debora Karetová, CSc. II. interní klinika kardiologie a angiologie, 1. LF UK, Praha
- 5 **Kombinační léčba hypertenze**
MUDr. Libor Jelínek I. interní klinika – kardiologická, FN Olomouc
- 5 **Betablokátor v sekundární prevenci po infarktu myokardu**
MUDr. Petr Janský Klinika kardiiovaskulární chirurgie 2. LF UK a FN v Motole, Praha
- 6 **Kardiovaskulárne ochorenia pri nealkoholevej metabolickej tukovej chorobe pečene**
MUDr. Marek Rác, Ph.D. Hepatologická ambulancia, Interná klinika, Fakultná nemocnica Nitra
- 6 **Fixní kombinace sakubitril/valsartan v léčbě srdečního selhání – studie TRANSITION**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 6 **Léčba diabetes mellitus u kardiovaskulárních onemocnění**
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika FN Brno, LF MU, Brno
prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardioangiologická klinika FN u sv. Anny v Brně a LF MU, Brno
- 7 **Léčba canagliflozinem snižuje riziko progresse renální insuficience a selhání ledvin u diabetiků 2. typu s nefropatií – výsledky studie CREDENCE**
prof. MUDr. Ivan Rychlík, CSc., FASN, FERA I. interní klinika 3. LF UK a FNKV, Praha
- 7 **Intenzifikace injekční léčby diabetes mellitus 2. typu**
MUDr. Denisa Janíčková Žďárská, Ph.D. Interní klinika 2. LF UK a FN v Motole, Praha
- 7 **Chronická pankreatitida – nová definice, diagnostika a enzymatická terapie**
prof. MUDr. Petr Dítě, DrSc. Interní klinika FN Ostrava, Lékařská fakulta Ostravské univerzity, IGEK FN Brno
MUDr. Martin Blaho Interní klinika FN Ostrava, Lékařská fakulta Ostravské univerzity
MUDr. Lumír Kunovský, Ph.D. IGEK FN Brno
MUDr. Martina Bojková Interní klinika FN Ostrava
MUDr. Bohuslav Kianička, Ph.D. II. interní klinika FN u sv. Anny v Brně
doc. MUDr. Arnošt Martínek, CSc. Interní klinika FN Ostrava, Lékařská fakulta Ostravské univerzity
- 8 **Vliv pomocných látek na stabilitu levothyroxinu a variabilitu jeho obsahu v preparátu Euthyrox**
MUDr. Mgr. Sylvie Špitálníková, Ph.D. Endokrinologická a diabetologická ambulance, Nemocnice Havlíčkův Brod, ambulance Hlinsko, Chotěboř
- 8 **Aktuální možnosti léčby chronické obstrukční plicní nemoci**
doc. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie 3. LF UK a Nemocnice Na Bulovce, Praha
- 8 **Pembrolizumab v léčbě nemalobuněčného plicního karcinomu**
MUDr. Marie Drösslerová Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 8 **Léčba HIV – současnost a výhledy**
MUDr. Svatava Snopková, Ph.D. | prof. MUDr. Petr Husa, CSc. Klinika infekčních chorob, FN a LF MU, Brno
- 9 **Hepatitida C – diagnóza, léčba a eliminace**
MUDr. Pavel Dlouhý Infekční oddělení a HIV centrum Masarykovy nemocnice v Ústí nad Labem

- 9 **Screening Fabryho choroby – v kardiologické ambulanci**
doc. MUDr. David Zemánek, Ph.D. II. interní klinika kardiologie a angiologie VFN a 1. LF UK, Praha
- 9 **Pacientka s Gaucherovou nemocí**
MUDr. Hana Ptoszková Klinika dětského lékařství FN Ostrava

Kombinační léčba hypertenze

prof. MUDr. Miroslav Souček, CSc. II. interní klinika a ICRC FN u sv. Anny v Brně a LF MU, Brno

- 1 Widimský, J. – Filipovský, J. – Ceral, J., et al.: Doporučení pro diagnostiku a léčbu arteriální hypertenze ČHS 2017. *Hypertenze – kardiovaskulární prevence*, 2018, suppl., s. 1–19.
- 2 Cífková, R. – Bruthans, J. – Adámková, V., et al.: Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MONIKA. *Cor Vasa*, 2011, 53, s. 220–229.
- 3 Gradman, A. H. – Parisé, H. – Lefebvre, P., et al.: Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. *Hypertension*, 2013, 61, s. 309–318.
- 4 Wald, D. S. – Law, M. – Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11.000 participants from 42 trials. *Am J Med*, 2009, 122, s. 290–300.
- 5 Filipovský, J. – Widimský, J. jr. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Hypertenze a kardiovaskulární prevence*, 2012, 3, s. 1–16.
- 6 Frank, J.: Managing hypertension using combination therapy. *Am Fam Physician*, 2008, 77, s. 1279–1286.
- 7 Egan, B. M. – Bandyopadhyay, D. – Shaftman, S. R., et al.: Initial monotherapy and combination therapy and hypertension control the first year. *Hypertension*, 2012, 59, s. 1124–1131.
- 8 Kociánová, E. – Václavík, J. – Táborský, M.: Fixní kombinace v léčbě hypertenze – přehled současných možností. *Kardiologie, výběr článků*, 2014, s. 19–22.
- 9 Bangalore, S. – Kamalakkannan, G. – Parkar, S., et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*, 2007, 120, s. 713–719.
- 10 Mancía, G. – Fagard, R. – Narkiewicz, K., et al.: ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*, 2013, 34, s. 2159–2219.
- 11 Corrao, G. – Nicotra, F. – Parodi, A., et al.: Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practise. *Hypertension*, 2011, 58, s. 566–572.
- 12 Messeri, F. H. – Makani, H. – Benjo, A., et al.: Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: A meta-analysis of randomized trials. *J Am Coll Cardiol*, 2011, 57, s. 590–600.
- 13 ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patient swith type 2 diabetes mellitus (the ADVANCE trial). *Lancet*, 2007, 370, s. 829–840.
- 14 PROGRESS Collaborative Study Group: Randomised trial of perindopril based blood pressure-lowering regimen among 6.108 individual swith previous stroke or transientis chemic attack. *Lancet*, 2007, 370, s. 1033–1041.
- 15 Becket, N. S. – Peters, R. – Fletcher, A. E., et al.; for the HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*, 2008, 358, s. 1887–1898.
- 16 Dahlöf, B. – Sever, P. S. – Poulter, N. R., et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomised controlled trial. *Lancet*, 2005, 366, s. 895–906.
- 17 Rothwell, P. – Howard, S. – Dolan, E., et al.: Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *Lancet*, 2010, 375, s. 895–905.
- 18 Jamerson, K. – Weber, M. A. – Bakris, G. L., et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*, 2008, 359, s. 2417–2428.
- 19 The ONTARGET Investigators: Telmisartan, ramipril, or both in patient-sat high risk for vascular events. *N Engl J Med*, 2008, 358, s. 1547–1559.
- 20 UK National Institute for hypertension in adults in primary care. 2006. NICE guidelines (CG34). Dostupné z: <http://www.nice.org.uk/CG034>, vyhledáno 3. 9. 2019.
- 21 Khan, N. – McAlister, F. A.: Re-examining the efficacy of betablockers for the treatment of hypertension: a meta-analysis. *CMAJ*, 2006, 174, s. 1737–1742.
- 22 Turnbull, F. – Niel, B. – Ninomiya, T., et al.; Pressure Lowering Treatment Trialists' Collaboration: Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *Blood GBMJ*, 2008, 336, s. 1121–1123.
- 23 Matuzaki, M. – Ogihara, T. – Umamoto, S., et al.; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group: Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. *J Hypertens*, 2011, 29, s. 1649–1659.
- 24 Kociánová, E. – Václavík, J. – Táborský, M.: Fixní kombinace v léčbě hypertenze – přehled současných možností. *Kardiologie, výběr článků*, 2014, s. 19–22.
- 25 Marrazi, G. – Volterrani, M. – Caminiti, G., et al.: Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. *Adv Ther*, 2010, 27, s. 655–664.
- 26 Neutel, J. M. – Smith, D. H.: Hypertension management: rationale for triple therapy based on mechanisms of action. *Cardiovasc Ther*, 2013, 31, s. 251–258.
- 27 Thoenes, M. – Neuberger, H. R. – Volpe, M., et al.: Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. *J Hum Hypertens*, 2010, 24, s. 336–344.
- 28 Chalmers, J. – Arima, H. – Woodward, M., et al.: Effects of combination perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus. results from the Action in Diabetes and Vascular Disease: Preterax and Diamicon Controlled Evaluation (ADVANCE) Trial. *Hypertension*, 2014, 63, s. 259–264.
- 29 Toth, K., and Investigators: Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: Results of the PIANIST Study. *Am J Cardiovasc Drug*, 2014, 14, s. 239.
- 30 Pall, D. – Szanto, I. – Szabo, Z.: Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. *Clin Drug Invest*, 2014, 34, s. 701–708.
- 31 Toth, K.: Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus Amlodipine in high risk hypertensive patients). *Am J Cardiol Vasc Drug*, 2014, 14, s. 137–145.
- 32 Gradman, A. H.: Rationale for triple-combination therapy for management of high blood pressure. *J Clin Hypertens*, 2010, 12, s. 869–878.
- 33 Makani, H. – Bangalore, S. – Romero, J., et al.: Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. *Am J Med*, 2011, 124, s. 128–135.
- 34 Sever, P. S. – Poulter, N. R. – Dahlöf, B., et al.: Antihypertensive therapy and the benefit of atorvastatin in the Anglo-Scandinavian cardiac outcomes trial: lipid-lowering arm extension. *J Hypertens*, 2009, 28, s. 947–954.
- 35 Bertrand, M. – Mourad, J. J.: Combining perindopril with calcium channel blockers and lipid-lowering agent significantly decreases mortality: a subgroup analysis of EUROPA. *Circulation*, 2013, 128, A18906.

Moderní léčba fibrilace síní

prof. MUDr. Josef Kautzner, CSc., FESC Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

- 1 Zulkifly, H. – Lip, G. Y. H. – Lane, D. A.: Epidemiology of atrial fibrillation. *Int J Clin Pract*, 2018, e13070, s. 1–7.
- 2 Lip, G. Y. H. – Kakar, P. – Watson, T.: Atrial fibrillation – the growing epidemic. *Heart*, 2007, 93, s. 542–543.
- 3 Kirchhof, P. – Benussi, S. – Kotecha, D., et al.: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace*, 2016, 18, s. 1609–1678.
- 4 Brambatti, M. – Connolly, S. J. – Gold, M. R., et al.: Temporal relationship between subclinical atrial fibrillation and embolic events. *Circulation*, 2014, 129, s. 2094–2099.
- 5 Hanon, S. – Shapiro, M. – Schweitzer, P.: A troubled beginning: Evolving concepts of an old arrhythmia. *J Electrocardiol*, 2005, 38, s. 213–217.
- 6 Nishida, K. – Datino, T. – Macle, L., et al.: Atrial fibrillation ablation: translating basic mechanistic insights to the patient. *J Am Coll Cardiol*, 2014, 64, s. 23–831.
- 7 Coplen, S. E. – Antman, E. M. – Berlin, J. A., et al.: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. *Circulation*, 1990, 82, s. 1106–1116.
- 8 Dhein, S. – Muller, A. – Gerwin, R., et al.: Comparative study on the proarrhythmic effects of some antiarrhythmic agents. *Circulation*, 1993, 87, s. 617–630.
- 9 Echt, D. S. – Liebson, P. R. – Mitchell, L. B., et al.: Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppression Trial. *New Engl J Med*, 1991, 324, s. 781–788.
- 10 Greene, H. L. – Roden, D. M. – Katz, T. J., et al.: The Cardiac Arrhythmia Suppression Trial: First CAST ... Then CAST-II. *J Am Coll Cardiol*, 1992, 19, s. 894–898.
- 11 Caldeira, D. – David, C. – Sampaio, C.: Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. *Arch Cardiovasc Dis*, 2012, 105, s. 226–238.
- 12 Corley, S. D. – Epstein, A. E. – DiMarco, J. P., et al.: Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. *Circulation*, 2004, 109, s. 1509–1513.
- 13 Van Hemel, N. M. – Defauw, J. J. A. M. – Guiraudon, G. M.: Long-term follow-up of corridor operation for lone atrial fibrillation: evidence for progression of disease? *J Cardiovasc Electrophysiol*, 1997, 8, s. 967–973.
- 14 Cox, J. L. – Schuessler, R. B. – Lappas, D. G., et al.: An 8 1/2-year clinical experience with surgery for atrial fibrillation. *Ann Surg*, 1996, 224, s. 267–273.
- 15 Haïssaguerre, M. – Jaïs, P. – Shah, D. C., et al.: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med*, 1998, 339, s. 659–666.
- 16 Savelieva, I. – Camm, J.: Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. *Europace*, 2008, 10, s. 647–665.
- 17 Dagens, N. – Lewalter, T. – Lip, G. Y. H., et al.: Current practice of anti-arrhythmic drug therapy for prevention of atrial fibrillation in Europe: The European Heart Rhythm Association survey. *Europace*, 2013, 15, s. 478–481.
- 18 Dan, G. A. – Martinez-Rubio, A. – Agewall, S., et al.: Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). *Europace*, 2018, 0, s. 1–42.
- 19 Hejman, J. – Chezelbash, S. – Dobrev, D.: Investigational antiarrhythmic agents: promising drugs in early clinical development. *Expert OpinInvestig Drugs*, 2017, 26, s. 897–907.
- 20 Calvo, D. – Filgueiras-Rama, D. – Jalife, J.: Mechanisms and drug development in atrial fibrillation. *Pharmacol Rev*, 2018, 70, s. 505–525.
- 21 Belluzzi, F. – Sernesi, L. – Preti, P., et al.: Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. *J Am Coll Cardiol*, 2009, 53, s. 24–29.
- 22 Zannad, F. – McMurray, J. J. – Krum, H., et al.; EMPHASIS-HF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med*, 2011, 364, s. 11–21.
- 23 Neefs, J. – van den Berg, N. W. – Limpens, J., et al.: Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. *Int J Cardiol*, 2017, 231, s. 155–161.
- 24 Kuhn, E. W. – Liakopoulos, O. J. – Stange, S., et al.: Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000 patients. *Eur J Cardiothorac Surg*, 2014, 45, s. 17–26.
- 25 Rienstra, M. – Hobbelt, A. H. – Alings, M., et al.: Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. *Eur Heart J*, 2018, 39, s. 2987–2996.
- 26 Pathak, R. K. – Elliott, A. – Middeldorp, M. E., et al.: Impact of CARDIO-respiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. *J Am Coll Cardiol*, 2015, 66, s. 985–996.
- 27 Calkins, H. – Hindricks, G. – Cappato, R., et al.: 2017 HRS / EHRA / ECAS / APHRS / SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. *Europace*, 2018, 20, s. 157–208.
- 28 Patel, N. J. – Maradey, J. A. – Bhavre, P. D.: Atrial fibrillation ablation: indications and techniques. *Curr Treat Options Cardio Med*, 2019, 21, s. 43.
- 29 Arbelo, E. – Brugada, J. – Blomström-Lundqvist, C., et al.: Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. *Eur Heart J*, 2017, 38, s. 1303–1316.
- 30 Cosedis Nielsen, J. – Johannessen, A. – Raatikainen, P., et al.: Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. *N Engl J Med*, 2012, 367, s. 1587–1595.
- 31 Kautzner, J. – Peichl, P. – Sramko, M., et al.: Catheter ablation of atrial fibrillation in elderly population. *J Geriatr Cardiol*, 2017, 14, s. 563–568.
- 32 Pearman, C. M. – Poon, S. S. – Bonnett, L. J., et al.: Minimally invasive epicardial surgical ablation alone versus hybrid ablation for atrial fibrillation: a systematic review and meta-analysis. *Arrhythm Electrophysiol Rev*, 2017, 6, s. 202–209.
- 33 Vroomen, M. – Pison, L.: Hybrid ablation for atrial fibrillation:

a systematic review. *J Interv Card Electrophysiol*, 2016, 47, s. 265–274.

34 Friberg, L. – Tabrizi, F. – Englund A.: Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. *Eur Heart J*, 2016, 37, s. 2478–2487.

35 Saliba, W. – Schliamser, J. E. – Lavi, I., et al.: Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: A propensity score-matched analysis. *Heart Rhythm*, 2017, 14,

s. 635–642.

36 Marrouche, N. F. – Brachmann, J. – Andresen, D., et al.: Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med*, 2018, 378, s. 417–427.

37 Packer, D. L. – Mark, D. B. – Robb, R. A., et al.: Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA

Randomized Clinical Trial. *JAMA*, 2019, 321, s. 1261–1274.

38 Aliot, E. – Brandes, A. – Eckardt, L., et al.: The EAST study: redefining the role of rhythm control therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial. *Eur Heart J*, 2015, 36, s. 255–256.

39 Garrey, W. E.: Auricular fibrillation. *Physiol Rev*, 1924, 4, s. 215–250.

Postavení betablokátorů v léčbě srdečního selhání

doc. MUDr. Vilém Danzig, Ph.D., FESC II. interní klinika VFN a 1. LF UK, Praha

1 Ponikowski P., et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2016, 37, s. 2129–2200.

2 Setoguchi, S., et al.: Repeated hospitalizations predict mortality in the community population with heart failure. *Am Heart J*, 2007, 154, s. 260–266.

3 Gheorghiade, M., et al.: Pathophysiologic targets in the early phase of acute heart failure syndromes. *Am J Cardiol*, 2005, 96, s. 11G–17G.

4 Piepoli, M. F. – Hoes, A. W. – Agewall, S., et al.: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

(constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*, 2016, 37, s. 2315–2381.

5 Flather, M. D., et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J*, 2005, 26, s. 215–225.

6 Rutten, F. H. – Zuihthoff, N. P. – Hak, E., et al.: Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. *Arch Intern Med*, 2010, 170, s. 880–887.

7 Silvestri, A., et al.: Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is

reversed by placebo. *Eur Heart J*, 2003, 24, s. 1928–1932.

8 CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet*, 1999, 353, s. 9–13.

9 MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*, 1999, 353, s. 2001–2007.

10 Deedwania, P. C. – Giles, T. D. – Klibaner, M., et al.: Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF. *Am Heart J*, 2005, 149, s. 159–167.

Kombinovaná léčba dyslipidemií

doc. MUDr. David Karásek, Ph.D. III. interní klinika – nefrologická, revmatologická a endokrinologická, FN Olomouc a LF UP, Olomouc

1 Writing Group Members, Mozaffarian, D. – Benjamin, E. J. – Go, A. S., et al.: American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics–2016 Update: A Report From the American Heart Association. *Circulation*, 2016, 133, e38–360.

2 Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney, P. M. – Blackwell, L. – Collins, R., et al.: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*, 2008, 371, s. 117–125.

3 Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent, C. – Blackwell, L. – Emberson, J., et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*, 2010, 376, s. 1670–1681.

4 Karalis, D. G. – Victor, B. – Aghor, L., et al.: Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. *Cholesterol*, 2012, 2012, 861924.

5 Catapano, A. L. – Graham, I. – De Backer, G., et al.: Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*, 2016, 37, s. 2999–3058.

6 Karásek, D.: Kombinovaná hypolipidemická léčba. *Vnitř Lék*, 2018, 64, s. 1177–1184.

7 Hennekens, C. H.: Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations. *Am J Cardiovasc Drugs*, 2008, 8, s. 155–160.

8 Vodonos, A. – Ostapenko, I. – Toledano, R., et al.: Statin adherence and LDL cholesterol levels. Should we assess adherence prior to statin upgrade? *Eur J Intern Med*, 2015, 26, s. 268–272.

9 Ho, P. M. – Magid, D. J. – Shetterly, S. M., et al.: Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. *Am Heart J*, 2008, 155, s. 772–779.

10 Pandor, A. – Ara, R. M. – Tumor, I., et al.: Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and metaanalysis of randomized controlled trials. *J Intern Med*, 2009, 265, s. 568–580.

11 Catapano, A. – Brady, W. E. – King, T. R., et al.: Lipid altering efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a metaanalysis of pooled data from 14 clinical trials. *Curr Med Res Opin*, 2005, 21, s. 1123–1130.

12 Ballantyne, C. M. – Hourii, J. – Notarbartolo, A., et al.: Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. *Circulation*, 2003, 107, s. 2409–2415.

13 Bays, H. E. – Avena, M. – Majul, C., et al.: Efficacy and safety of ezetimibe addend to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. *Am J Cardiol*, 2013, 112, s. 1885–1895.

14 Ballantyne, C. M. – Hoogveen, R. C. – Raya, J. L., et al.: GRAVITY Study Investigators: Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. *Atherosclerosis*, 2014, 232, s. 86–93.

15 Ballantyne, C. M. – Weiss, R. – Moccetti, T., et al.: EXPLORER Study Investigators: Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). *Am J Cardiol*, 2007, 99,

s. 673–680.

16 Cannon, C. P. – Blazing, M. A. – Giugliano, R. P., et al.: IMPROVE-IT Investigators: Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*, 2015, 372, s. 2387–2397.

17 Giugliano, R. P. – Cannon, C. P. – Blazing, M. A., et al.: IMPROVE-IT (Improved Reduction of Outcomes: Ytorin Efficacy International Trial) Investigators: Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Ytorin Efficacy International Trial). *Circulation*, 2018, 137, s. 1571–1582.

18 Bonaca, M. P. – Gutierrez, J. A. – Cannon, C., et al.: Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. *Lancet Diabetes Endocrinol*, 2018, 6, s. 934–943.

19 Eisen, A. – Cannon, C. P. – Blazing, M. A., et al.: IMPROVE-IT Investigators: The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. *Eur Heart J*, 2016, 37, s. 3576–3584.

20 Bohula, E. A. – Morrow, D. A. – Giugliano, R. P., et al.: Atherothrombotic risk stratification and ezetimibe for secondary prevention. *J Am Coll Cardiol*, 2017, 69, s. 911–921.

21 Navar, A. M. – Roe, M. T. – White, J. A., et al.: Medication discontinuation in the IMPROVE-IT trial. *Circ Cardiovasc Qual Outcomes*, 2019, 12, e005041.

22 Keech, A. – Simes, R. J. – Barter, P., et al.: FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*, 2005, 366, s. 1849–1861.

23 ACCORD Study Group, Ginsberg, H. N. – Elam, M. B. – Lovato, L. C., et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*, 2010, 362, s. 1563–1574.

24 Elam, M. – Lovato, L. – Ginsberg, H.: The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. *Clin Lipidol*, 2011, 6, s. 9–20.

25 Elam, M. B. – Ginsberg, H. N. – Lovato, L. C., et al.: ACCORDION Study Investigators: Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. *JAMA Cardiol*, 2017, 2, s. 370–380.

26 Lee, M. – Saver, J. L. – Towfighi, A., et al.: Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a metaanalysis. *Atherosclerosis*, 2011, 217, s. 492–498.

27 Farnier, M. – Freeman, M. W. – Macdonell, G., et al.: Ezetimibe Study Group: Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. *Eur Heart J*, 2005, 26, s. 897–905.

28 McKenney, J. M. – Farnier, M. – Lo, K. W., et al.: Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. *J Am Coll Cardiol*, 2006, 47, s. 1584–1587.

29 Shinnakasu, A. – Yamamoto, K. – Kurano, M., et al.: The combination therapy of fenofibrate and ezetimibe improved lipid profile and vascular function compared with statins in patients with type 2 diabetes. *J Atheroscler Thromb*, 2017, 24, s. 735–748.

30 Kumar, S. S. – Lahey, K. A. – Day, A., et al.: Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. *Lipids*

Health Dis, 2009, 8, s. 56.

31 Nobecourt, E. – Cariou, B. – Lambert, G., et al.: Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series. *J Clin Lipidol*, 2017, 11, s. 289–293.

32 Farnier, M. – Retterstøl, K. – Steinmetz, A., et al.: Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease. *Diab Vasc Dis Res*, 2012, 9, s. 205–215.

33 Jones, P. H. – Goldberg, A. C. – Knapp, H. R., et al.: Efficacy and safety of fenofibrate in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. *Am Heart J*, 2010, 160, s. 759–766.

34 Češka, R. – Táborský, M. – Vrablík, M.: Společné stanovisko odborných společností k předepisování PCSK9 inhibitorů. *Athero Rev*, 2018, 3, s. 161–168.

35 Navarese, E. P. – Kolodziejczak, M. – Schulze, V., et al.: Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and metaanalysis. *Ann Intern Med*, 2015, 163, s. 40–51.

36 Squizzato, A. – Suter, M. B. – Nerone, M., et al.: PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a metaanalysis. *Intern Emerg Med*, 2017, 12, s. 1043–1053.

37 Zhang, J. – Tecson, K. M. – Rocha, N. A., et al.: Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia. *Proc (Bayl Univ Med Cent)*, 2018, 31, s. 180–184.

38 Ray, K. K. – Leiter, L. A. – Müller-Wieland, D., et al.: Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. *Diabetes Obes Metab*, 2018, 20, s. 1479–1489.

39 Sabatine, M. S. – Giugliano, R. P. – Keech, A. C., et al.: FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*, 2017, 376, s. 1713–1722.

40 Schwartz, G. G. – Steg, P. G. – Szarek, M., et al.: ODYSSEY OUTCOMES Committees and Investigators: Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*, 2018, 379, s. 2097–2107.

41 Ridker, P. M. – Revkin, J. – Amarenco, P., et al.: SPIRE Cardiovascular Outcome Investigators: Cardiovascular efficacy and safety of boccuzumab in high-risk patients. *N Engl J Med*, 2017, 376, s. 1527–1539.

42 Sabatine, M. S. – De Ferrari, G. M. – Giugliano, R. P., et al.: Clinical benefit of evolocumab by severity and extent of coronary artery disease. *Circulation*, 2018, 138, s. 756–766.

43 Bonaca, M. P. – Nault, P. – Giugliano, R. P., et al.: Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). *Circulation*, 2018, 137, s. 338–350.

44 Jukema, J. W. – Szarek, M. – Zijlstra, L. E., et al.: ODYSSEY OUTCOMES Committees and Investigators: Patients with recent acute coronary syndrome and polyvascular disease derive large absolute benefit from alirocumab: ODYSSEY OUTCOMES trial. *J Am Coll Cardiol*, 2019, pii, S0735-1097(19)33921-X.

45 Landmesser, U. – Chapman, M. J. – Stock, J. K., et al.: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein

convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. *Eur Heart J*, 2018, 39, s. 1131–1143.

46 Yokoyama, M. – Origasa, H. – Matsuzaki, M., et al.; Japan EPA lipid intervention study (JELIS) Investigators: Effects of eicosapentaenoic acid

on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet*, 2007, 369, s. 1090–1098.

47 Bhatt, D. L. – Steg, P. G. – Miller, M., et al.; REDUCE-IT Investigators: Cardiovascular risk reduction with icosapent ethyl for

hypertriglyceridemia. *N Engl J Med*, 2019, 380, s. 11–22.

48 Nicholls, S. J. – Lincoff, A. M. – Bash, D., et al.: Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. *Clin Cardiol*, 2018, 41, s. 1281–1288.

Postavení enoxaparínu ve spektru současných antikoagulantů

prof. MUDr. Jan Bultas, CSc. Farmakologický ústav, 3. LF UK, Praha

doc. MUDr. Debora Karetová, CSc. II. interní klinika kardiologie a angiologie, 1. LF UK, Praha

1 Alturkistani, A., et al.: Inhibition of PAR-1 receptor signaling by enoxaparin reduces cell proliferation and migration in A549 cells. *Anticancer Res*, 2019, 39, s. 5297–5310.

2 Muszbek, L., et al.: Antithrombin deficiency and its laboratory

diagnosis. *Clin Chem Lab Med*, 2010, 48, suppl. 1, s. S67–S78.

3 Harbrecht, U.: Old and new anticoagulants. *Hamostaseologie*, 2011, 31, s. 21–27.

4 Rupprecht, H. J. – Blank, R.: Clinical pharmacology of direct and

indirect factor Xa inhibitors. *Drugs*, 2010, 70, s. 2153–2170.

5 Antman, E. M., et al.: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. *Circulation*, 1999, 100, s. 1602–1608.

Kombinační léčba hypertenze

MUDr. Libor Jelínek I. interní klinika – kardiologická, FN Olomouc

1 Forouzanfar, M. H. – Liu, P. – Roth, G. A., et al.: Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. *JAMA*, 2017, 317, s. 165–182.

2 Chow, C. K. – Teo, K. K. – Rangarajan, S., et al.: Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. *JAMA*, 2013, 310, s. 959–968.

3 Cifková, R., et al.: The prevalence of major cardiovascular risk factors in the Czech population in 2006–2009. The Czech post-MONICA study. *Cor Vasa*, 2011, 53, s. 220–229.

4 Ettehad, D., et al.: Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*, 2016, 387, s. 957–967.

5 Fryar, C. D. – Ostchega, Y. – Hales, C. M., et al.: Hypertension prevalence and control among adults: United States, 2015–2016. *NCHS Data Brief*, 2017, 289, s. 1–8.

6 Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*, 2018, 39, s. 3021–3104.

7 Guerrero-García, C. – Rubio-Guerra, A. F.: Combination therapy in the treatment of hypertension. *Drugs Context*, 2018, 7, 212531, doi: 10.7573/dic.212531.

8 Kaplan, N. M.: *Kaplan's clinical hypertension*. 2005, Lippincott Williams & Wilkins, Philadelphia, USA. *Can J Cardiol*, 2007, 23, s. 605.

9 de la Sierra, A.: Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. *J Hum Hypertens*, 2009, 23, s. 503–511.

10 Fuchs, F. D. – Gus, M. – Ribeiro, J. P.: ASCOT-BPLA. *Lancet*, 2006, 367, s. 205.

11 Jamerson, K. – Weber, M. A. – Bakris, G. L., et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*, 2008, 359, s. 2417–2428.

12 van Vark, L. C. – Bertrand, M. – Akkerhuis, K. M., et al.: Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. *Eur Heart J*, 2012, 33, s. 2088–2097.

13 Taddei, S.: Combination therapy in hypertension: What are the best options according to clinical pharmacology principles and controlled clinical trial evidence? *Am J Cardiovasc Drugs*, 2015, 15, s. 185–194.

14 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The antihypertensive and lipid-lowering treatment to prevent heart attack trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*, 2002, 288, s. 2981–2997.

15 Neutel, J. – Smith, D. H. G. – Weber, M. A.: Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. *Am J Hypertens*, 2004, 17, s. 37–42.

16 Brown, M. J. – Williams, B. – Morant, S. V., et al.: Effect of amloride, or amloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. *Lancet Diabetes Endocrinol*, 2016, 4, s. 136–147.

17 Matsuzaki, M. – Ogihara, T. – Umemoto, S., et al.: Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. *J Hypertens*, 2011, 29, s. 1649–1659.

18 Rimoldi, S. F. – Messerli, F. H. – Chavez, P., et al.: Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. *J Clin Hypertens* (Greenwich), 2015, 17, s. 193–199.

19 Tóth, K.; PIANIST Investigators: Antihypertensive efficacy of triple

combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus Amlodipine in high risk hypertensive patients). *Am J Cardiovasc Drugs*, 2014, 14, s. 137–145.

20 Daugherty, S. L. – Powers, J. D. – Magid, D. J., et al.: Incidence and prognosis of resistant hypertension in hypertensive patients. *Circulation*, 2012, 125, s. 1635–1642.

21 Williams, B. – MacDonald, T. M. – Morant, S., et al.: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. *Lancet*, 2015, 386, s. 2059–2068.

22 Jounela, A. L. – Kanninen, E. – Lilja, M.: Interaction between clonidine and alpha blockers. *Clin Cardiol*, 1985, 8, s. 641–642.

23 Bailey, D. G. – Carruthers, S. G.: Interaction between oral verapamil and β -blockers during submaximal exercise: Relevance of ancillary properties. *Clin Pharmacol Ther*, 1991, 49, s. 370–376.

24 Corrao, G., et al.: Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. *J Hypertens*, 2008, 26, s. 819–824.

25 Lilja, M. – Jounela, A. J. – Juustila, H., et al.: Interaction of clonidine and beta-blockers. *Acta Med Scand*, 1980, 207, s. 173–176.

26 Ceral, J. – Habrdova, V. – Vorisek, V., et al.: Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. *Hypertens Res*, 2011, 34, s. 87–90.

27 Gupta, A. S. – Arshad, S. – Poulter, N. R.: Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. *Hypertension*, 2010, 55, s. 399–407.

Betablokátory v sekundární prevenci po infarktu myokardu

MUDr. Petr Janský Klinika kardiovaskulární chirurgie 2. LF UK a FN v Motole, Praha

1 Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. *N Engl J Med*, 1981, 304, s. 801–807.

2 Pedersen, T. R.: Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. *N Engl J Med*, 1985, 313, s. 1055–1058.

3 A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. Autoři neuvedeni. *JAMA*, 1982, 247, s. 1707–1714.

4 Hjalmarson, A. – Herlitz, J. – Holmberg, S., et al.: The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. *Circulation*, 1983, 67, s. 126–132.

5 The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. *Eur Heart J*, 1985, 6, s. 199–226.

6 Olsson, G. – Rehnqvist, N. – Sjögren, A., et al.: Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. *J Am Coll Cardiol*, 1985, 5, s. 1428–1437.

7 Olsson, G. – Wikstrand, J. – Warnold, I., et al.: Metoprolol-induced reduction in post infarction mortality: pooled results from five

double-blind randomized trials. *Eur Heart J*, 1992, 13, s. 28–32.

8 Freemantle, N. – Cleland, J. – Young, P., et al.: Betablockade after myocardial infarction: systematic review and meta regression analysis. *BMJ*, 1999, 318, s. 1730–1737.

9 Dargie, H. J.: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet*, 2001, 357, s. 1385–1390.

10 Chen, Z. M. – Pan, H. C. – Chen, Y. P., et al.: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet*, 2005, 366, s. 1622–1632.

11 Bangalore, S. – Makani, H. – Radford, M., et al.: Clinical outcomes with β -blockers for myocardial infarction: a meta-analysis of randomized trials. *Am J Med*, 2014, 127, s. 939–953.

12 Elgendy, I. Y. – Elgendy, A. Y. – Mahmoud, A. N., et al.: Intravenous β -blockers for patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials. *Int J Cardiol*, 2016, 223, s. 891–897.

13 Raposeiras-Roubin, S. – Abu-Asi, E. – Redondo-Díez, A., et al.: Prognostic benefit of beta-blockers after acute coronary syndrome with preserved systolic function. Still relevant today? *Rev Esp Cardiol*,

2015, 68, s. 585–591.

14 Neumann, A. – Maura, G. – Weill, A., et al.: Clinical events after discontinuation of β -blockers in patients with out heart failure optimally treated after acute myocardial infarction: a cohort study on the French Health care Databases. *Circ Cardiovasc Qual Outcomes*, 2018, 11, s. e004356.

15 Huang, B. T. – Huang, F. Y. – Zuo, Z. L., et al.: Meta-analysis of relation between oral β -blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. *Am J Cardiol*, 2015, 115, s. 1529–1538.

16 Dahl Aarvik, M. – Sandven, I. – Dondo, T. B., et al.: Effect of oral β -blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother*, 2019, 5, s. 12–20.

17 Ibanez, B. – James, S. – Agewall, S., et al.: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*, 2018, 39, s. 119–177.

Kardiovaskulárne ochorenia pri nealkoholevej metabolickej tukovej chorobe pečene

MUDr. Marek Rác, PhD. Hepatologická ambulancia, Interná klinika, Fakultná nemocnica Nitra

- Ekstedt, M. – Franzén, L. E. – Mathiesen, U. L., et al.: Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology*, 2006, 44, s. 865–873.
- Ratzl, V. – Bellentani, S. – Cortez-Pinto, H., et al.: A position statement on NAFLD/NASH based on the EASL 2009 special conference. *J Hepatol*, 2010, 53, s. 372–384.
- Porepa, L. – Ray, J. G. – Sanchez-Romeu, P., et al.: Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. *Can Med Assoc J*, 2010, 182, s. E526–E531.
- Chalasani, N. – Younossi, Z. – Lavine, J. E., et al.: The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology*, 2012, 55, s. 2005–2038.
- Tran, T. T. – Changsri, C. – Shackleton, C., et al.: Living donor liver transplantation: Histological abnormalities found on liver biopsies of apparently healthy potential donors. *J Gastroenterol Hepatol*, 2006, 21, s. 381–383.
- Gholam, P. M. – Flancbaum, L. – Machan, J. T., et al.: Nonalcoholic fatty liver disease in severely obese subjects. *Am J Gastroenterol*, 2007, 102, s. 399–408.
- McCullough, A. J.: Pathophysiology of nonalcoholic steatohepatitis. *J Clin Gastroenterol*, 2006, 40, suppl. 1, s. S17–S29.
- Bhala, N. – Angulo, P. – van der Poorten, D., et al.: The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. *Hepatology*, 2011, 54, s. 1208–1216.
- Valenti, L. – Romeo, S. – Nobili, V., et al.: Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood. *J Hepatol*, 2016, 65, s. 1218–1229.
- Liu, Y.-L. – Patman, G. L. – Leathart, J. B. S., et al.: Carriage of the PNPLA3 rs738409 C & G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. *J Hepatol*, 2014, 61, s. 75–81.
- Aljada, A. – Mousa, S. A.: Metformin and neoplasia: Implications and indications. *Pharmacol Ther*, 2012, 133, s. 108–115.
- Chen, H.-P. – Shieh, J.-J. – Chang, C.-C., et al.: Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. *Gut*, 2013, 62, s. 606–615.
- Singh, S. – Singh, P. P. – Singh, A. G., et al.: Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. *Gastroenterology*, 2013, 144, s. 323–332.
- Rác, M. – Koller, T. – Jarčuška, P.: Nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC): single centre experience. *Inflamm Intest Dis*, 2017, 2, s. 55.
- Azzam, H. – Malnick, S.: Non-alcoholic fatty liver disease – the heart of the matter. *World J Hepatol*, 2015, 7, s. 1369.
- Rafiq, N. – Bai, C. – Fang, Y., et al.: Long-term follow-up of patients with nonalcoholic fatty liver. *Clin Gastroenterol Hepatol*, 2009, 7, s. 234–238.
- Schindhelm, R. K. – Dekker, J. M. – Nijpels, G., et al.: Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study. *Atherosclerosis*, 2007, 191, s. 391–396.
- Sookoian, S. – Pirola, C. J.: Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. *J Hepatol*, 2008, 49, s. 600–607.
- Fraser, A. – Harris, R. – Sattar, N., et al.: Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the british women's heart and health study and meta-analysis. *Arterioscler Thromb Vasc Biol*, 2007, 27, s. 2729–2735.
- Targher, G. – Bertolini, L. – Padovani, R., et al.: Relations between carotid artery wall thickness and liver histology in subjects with non-alcoholic fatty liver disease. *Diabetes Care*, 2006, 29, s. 1325–1330.
- Kim, D. – Choi, S.-Y. – Park, E. H., et al.: Nonalcoholic fatty liver disease is associated with coronary artery calcification. *Hepatology*, 2012, 56, s. 605–613.
- Mirbagheri, S. A. – Rashidi, A. – Abdi, S., et al.: Liver: an alarm for the heart? *Liver Int*, 2007, 27, s. 891–894.
- Lee, S. B. – Park, G.-M. – Lee, J.-Y., et al.: Association between non-alcoholic fatty liver disease and non-alcoholic coronary atherosclerosis: An observational cohort study. *J Hepatol*, 2018, 68, s. 1018–1024.
- Targher, G. – Day, C. P. – Bonora, E.: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med*, 2010, 363, s. 1341–1350.
- Akabame, S. – Hamaguchi, M. – Tomiyasu, K.-I., et al.: Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). *Circ J*, 2008, 72, s. 618–625. Dostupné z: <http://www.ncbi.nlm.nih.gov/pubmed/18362435>, vyhledáno 23. 4. 2018.
- Ağaç, M. T. – Korkmaz, L. – Çavuşoğlu, G., et al.: Association between nonalcoholic fatty liver disease and coronary artery disease complexity in patients with acute coronary syndrome. *Angiology*, 2013, 64, s. 604–608.
- Boddi, M. – Tarquini, R. – Chiostrì, M., et al.: Nonalcoholic fatty liver

- in nondiabetic patients with acute coronary syndromes. *Eur J Clin Invest*, 2013, 43, s. 429–438.
- Perseghin, G. – Lattuada, G. – De Cobelli, F., et al.: Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. *Hepatology*, 2007, 47, s. 51–58.
- Sung, K.-C. – Ryu, S. – Kim, B.-S., et al.: γ -glutamyl transferase is associated with mortality outcomes independently of fatty liver. *Clin Chem*, 2015, 61, s. 1173–1181.
- Wang, Z. – Roberts, A. B. – Buffa, J. A., et al.: Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. *Cell*, 2015, 163, s. 585–595.
- Adolph, T. – Grander, C. – Grabherr, F., et al.: Adipokines and non-alcoholic fatty liver disease: multiple interactions. *Int J Mol Sci*, 2017, 18, s. 1649.
- Targher, G. – Mantovani, A. – Pichiri, I., et al.: Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. *Clin Sci*, 2013, 125, s. 301–310.
- Newton, J. L. – Paiman, J. – Wilton, K., et al.: Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. *Clin Auton Res*, 2009, 19, s. 319–326.
- Targher, G. – Balbusa, F. – Bonapace, S., et al.: Association of non-alcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. *Nutr Metab Cardiovasc Dis*, 2014, 24, s. 663–669.
- Blais, P. – Lin, M. – Kramer, J. R., et al.: Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. *Dig Dis Sci*, 2016, 61, s. 1714–1720.
- Athyros, V. G. – Tziomalos, K. – Gossios, T. D., et al.: Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. *Lancet*, 2010, 376, s. 1916–1922.
- Chung, J. – An, S. H. – Kang, S. W., et al.: Ursodeoxycholic acid (UDCA) exerts anti-atherogenic effects by inhibiting RAGE signaling in diabetic atherosclerosis. *PLoS One*, 2016, 11, e0147839, doi:10.1371/journal.pone.0147839.
- Schultz, F. – Hasan, A. – Alvarez-Laviada, A., et al.: The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts. *Progress in Biophysics and Molecular Biology*, 2016, 120, s. 149–163.

Fixní kombinace sakubitril/valsartan v léčbě srdečního selhání – studie TRANSITION

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2016, 37, s. 2129–2200.
- Stewart, S. – MacIntyre, K. – Hole, D. J., et al.: More 'malignant' than cancer? Five-year survival following a first admission for heart failure. *Eur J Heart Fail*, 2001, 3, s. 315–322.
- McMurray, J. J. – Packer, M. – Desai, A. S., et al.; PARADIGM-HF Investigators and Committees: Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*, 2014, 371, s. 993–1004.
- Mogensen, U. M. – Køber, L. – Kristensen, S. L., et al.; PARADIGM-HF Investigators and Committees: The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. *Am Heart J*, 2017, 188, s. 35–41.
- Velazquez, E. J. – Morrow, D. A. – DeVore, A. D.; PIONEER-HF Investigators: Angiotensin-neprilysin inhibition in acute decompensated heart failure. *N Engl J Med*, 2019, 380, s. 539–548.
- Wachter, R. – Senni, M. – Belohlavek, J., et al.; TRANSITION Investigators: Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. *Eur J Heart Fail*, 2019, 21, s. 998–1007.

Léčba diabetes mellitus u kardiovaskulárních onemocnění

prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika FN Brno, LF MU, Brno

prof. MUDr. Lenka Špinarová, Ph.D., FESC | prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika FN u sv. Anny v Brně a LF MU, Brno

- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2016, 37, s. 2129–2200.
- American diabetes association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2018. *Diabetes Care*, 2018, 41, s. 86–104.
- Mudaliar, S. – Alloju, S. – Henry, R. R.: Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. *Diabetes Care*, 2016, 39, s. 1115–1122.
- Neal, B. – Perkovic, P. – Mahaffey, K. W., et al.: Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*, 2017, 377, s. 644–657.
- Niessner, A. – Tamargo, J. – Koller, L., et al.: Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J*, 2018, 39, s. 2274–2281.
- Packer, M.: Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control. *Diabetes Obes Metab*, 2018, 20, s. 1766–1769.
- Pipoli, M. F. – Hoes, A. V. – Egevall, S. S., et al.: 2016 European Guidelines on cardiovascular disease prevention. *Eur Heart J*, 2016, 37, s. 2315–2381.
- Olšovský, J.: Insulinová terapie DM2T. In: Karen, I. – Svačina, Š.: *Diabetes mellitus v primární péči*. Axonite, Praha, 2011, s. 98–106.
- Seferovic, P. E. – Petrie, M. C. – Filipatos, G. S., et al.: Type 2 diabetes mellitus and heart failure: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J*, 2018, 39, doi:10.1002/ehfj.1170.
- Špinar, J. – Špinarová, L. – Vítovec, J.: Position statement ESC k perorálním antidiabetikům a srdečnímu selhání. *Acta Medicinæ*, 2019, 2–3, s. 12–15.
- Špinar, J. – Hradec, J. – Špinarová, L. – Vítovec, J.: *Souhrn doporučených postupů ESC pro diagnózu a léčbu akutního a chronického srdečního selhání z roku 2016*. Přípraven Českou kardiologickou společností, 2016, 58, s. 455–494.
- Špinar, J. – Špinarová, L. – Vítovec, J.: Nová antidiabetika z pohledu kardiologa. *Acta medicinæ*, 2018, 8, s. 12–14.

- 13 Vítovec, J. – Špinar, J. – Špinarová, L.: Diabetes mellitus a kardiovaskulární onemocnění. *Kardiologická revue a Interní medicína*, 2018, 20, s. 118–125.
- 14 Vítovec, J. – Špinar, J. – Špinarová, L.: Glifloziny – naděje pro diabetiky s kardiovaskulárním onemocněním. *Acta Medicinæ*, 2018, 2–3, s. 71–73.
- 15 Wiviott, S. D. – Raz, M. – Bonaca, O., et al.: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2019, 380, s. 347–357.
- 16 Zelniger, T. A. – Wiviott, S. D. – Raz, I., et al.: SGLT2 inhibitors for

primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trial. *Lancet*, 2019, 393, s. 31–39.

Léčba canagliflozinem snižuje riziko progresse renální insuficience a selhání ledvin u diabetiků 2. typu s nefropatií – výsledky studie CREDENCE

prof. MUDr. Ivan Rychlík, CSc., FASN, FERA I. interní klinika 3. LF UK a FNKV, Praha

- 1 Brenner, B. M. – Cooper, M. E. – de Zeeuw, D., et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*, 2001, 345, s. 861–869.
- 2 Lewis, E. J. – Hunsicker, L. G. – Clarke, W. R., et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med*, 2001, 345, s. 851–860.
- 3 Wiviott, S. D. – Raz, I. – Bonaca, M. P., et al.: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2019, 380, s. 347–357.
- 4 Perkovic, V. – Jardine, M. J. – Neal, B., et al.: for the CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*, 2019, 380, s. 295–2306.
- 5 Liyanage, T. – Ninomiya, T. – Jha, V., et al.: Worldwide access to treatment for end-stage kidney disease: a systematic review. *Lancet*, 2015, 385, s. 1975–1982.
- 6 Cherney, D. Z. – Perkins, B. A. – Soleymanlou, N., et al.: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. *Circulation*, 2014, 129, s. 587–597.
- 7 Sarafidis, P. – Ferro, C. J. – Morales, E., et al.: SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. *Nephrol Dial Transplant*, 2019, 34, s. 208–234.
- 8 Inzucchi, S. E. – Iliiev, H. – Pfarrer, E., et al.: Empagliflozin and assessment of lower limb amputations in the EMPA-REG OUTCOME trial. *Diabetes Care*, 2018, 41, s. e4–e5.

Intenzifikace injekční léčby diabetes mellitus 2. typu

MUDr. Denisa Janíčková Žďárská, Ph.D. Interní klinika 2. LF UK a FN v Motole, Praha

- 1 Ringborg, A. – Lindgren, P. – Yin, D. D., et al.: Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. *Diabetes Metab*, 2010, 36, s. 198–203.
- 2 Machado-Alba, J. E. – Machado-Duque, M. E. – Moreno-Gutiérrez, P. A.: Time to and factors associated with insulin initiation in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract*, 2015, 107, s. 332–337.
- 3 Raccach, D.: Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options. *Diabetes Metab*, 2017, 43, s. 110–124.
- 4 Davies, M. J. – D'Alessio, D. A. – Fradkin, J., et al.: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*, 2018, 61, s. 2461–2498.
- 5 Marso, S. P. – Daniels, G. H. – Brown-Frandsen, K., et al.: Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2016, 375, s. 311–322.
- 6 Marso, S. P. – Bain, S. C. – Consoli, A., et al.: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*, 2016, 375, s. 1834–1844.
- 7 Gerstein, H. C. – Colhoun, H. M. – Dagenais, G. R., et al.: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*, 7. 6. 2019, pii: S0140-6736(19)31149-131143.
- 8 Rosenstock, J. – Aronson, R. – Grunberger, G., et al.: Benefits of Lixi-lan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The Lixi-Lan-O randomized trial. *Diabetes Care*, 2016, 39, s. 2026–2035.
- 9 Goldenberg, R. M. – Berard, L.: Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. *Curr Med Res Opin*, 2018, 34, s. 1–10.
- 10 Souhrn údajů o přípravku Suliqua, www.sukl.cz.
- 11 Souhrn údajů o přípravku Xultophy, www.sukl.cz.
- 12 Maiorino, M. I. – Chiodini, P. – Bellastella, G., et al.: Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Obes Metab*, 2018, 20, s. 2309–2313.
- 13 Sayre, T. – Shah, R. – Thomas, J., et al.: Network meta-analysis of iGlarLixi, a fixed-ratio combination GLP-1 RA and basal insulin versus premix. Poster –0534, IDF 2017, Abú Dhabí, Spojené arabské emiráty.
- 14 Meier, J. – Anderson, J. – Wysham, C., et al.: Propensity-score matched patient-level comparison of iGlarLixi and basal-bolus regimen in patients with type 2 diabetes. Poster 786, EASD 2018 Berlín, Německo.

Chronická pankreatitida – nová definice, diagnostika a enzymatická terapie

prof. MUDr. Petr Dítě, DrSc. Interní klinika FN Ostrava, Lékařská fakulta Ostravské univerzity, IGEK FN Brno

MUDr. Martin Blaho Interní klinika FN Ostrava, Lékařská fakulta Ostravské univerzity

MUDr. Lumír Kunovský, Ph.D. IGEK FN Brno

MUDr. Martina Bojková Interní klinika FN Ostrava

MUDr. Bohuslav Kianička, Ph.D. II. interní klinika FN u sv. Anny v Brně

doc. MUDr. Arnošt Martinek, CSc. Interní klinika FN Ostrava, Lékařská fakulta Ostravské univerzity

- 1 Dítě, P. – Starý, K. – Novotný, I., et al.: Incidence of chronic pancreatitis in the Czech Republic. *Europ J Gastroenterol Hepatol*, 2001, 13, s. 749–750.
- 2 Etemad, D. – Whitcomb, D. C.: Chronic pancreatitis, diagnosis, classification, and new genetic developments. *Gastroenterology*, 2001, 120, s. 682–707.
- 3 Steer, M. L. – Waxman, I. – Freedman, S.: Chronic pancreatitis. *N Engl J Med*, 1995, 332, s. 1482–1490.
- 4 Whitcomb, D. C. – Frulloni, L. – Garg, P., et al.: Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definition. *Pancreatology*, 2016, 16, s. 218–224.
- 5 Rana, S. S. – Vilman, P.: Endoscopic ultrasound features of chronic pancreatitis. *Endosc Ultrasound*, 2015, 4, s. 10–14.
- 6 Tricudanathan, G. – Muniga, L. S., Barlass, U., et al.: Evaluation of Rosemont criteria from noncalcific chronic pancreatitis based on histopathology: a retrospective study. *Pancreatology*, 2017, 17, s. 63–69.
- 7 Sainani, N. I. – Kadiyala, V. – Morteale, K., et al.: Evaluation of quantitative magnetic resonance imaging features for diagnosis of chronic pancreatitis. *Pancreas*, 2015, 44, s. 1280–1288.
- 8 Tirkes, T. – Fogel, E. L. – Sherman, S., et al.: Detection of exocrine dysfunction by MRI with early chronic pancreatitis. *Abdom Radiol*, 2017, 12, s. 544–551.
- 9 Aman, S. T. – Bishop, M. – Cunington, C., et al.: Fecal pancreatic elastase-1 is inaccurate in diagnosis of chronic pancreatitis. *Pancreas*, 1996, 13, s. 226–230.
- 10 Dominguez-Munoz, J. E. – Nieto, L. – Vilarino, M., et al.: Development and diagnostic of accuracy a breath test for pancreatic exocrine insufficiency in chronic pancreatitis. *Pancreas*, 2016, 45, s. 241–247.
- 11 Levy, P. – Dominguez-Munoz, J. E. – Imrie, C., et al.: Epidemiology of chronic pancreatitis: burden of the disease and consequences. *UEG Journal*, 2016, 20, s. 222–227.
- 12 Derix, M. H. – Kovacs, P. – Scholz, M., et al.: Pan-European working group on alcoholic chronic pancreatitis members and collaborators. Polymorphism at PRSS1-PRSS2 and CLDN2- MORC4 loci associate with alcoholic and nonalcoholic chronic pancreatitis in European replication study. *Gut*, 2015, 64, s. 1326–1434.
- 13 Sun, C. – Liu, M. Y. – Hu, L. H., et al.: Serin protease inhibitor Kazal type 1 / SPINK 1/c. 194+21>C station may predict long-term outcome of endoscopic treatment in idiopathic chronic pancreatitis. *Medicine*, 2015, 94, s. e2046.
- 14 Midha, S. – Sreenivas, V. – Kabra, M., et al.: Genetically determined chronic pancreatitis but not alcoholic pancreatitis is a strong risk factor for pancreatic cancer. *Pancreas*, 2016, 45, s. 478–484.
- 15 Yang, D. – Forsmark, Ch. E.: Chronic pancreatitis. *Curr Opin Gastroenterol*, 2017, 33, s. 398–403.
- 16 Yang, C. J. – Bliss, L. A. – Freedman, S. D., et al.: Surgery for chronic pancreatitis: the role of early surgery in pain management. *Pancreas*, 2015, 48, s. 819–823.
- 17 Ahmed, A. – Issa, Y. – Bruno, M. J., et al.: Dutch pancreatitis study group: Early surgery versus optimal current step-up practice for chronic pancreatitis /ESCAPE/ design and rationale of a randomized trial. *BMC Gastroenterol*, 2013, 13, s. 49.
- 18 Oh, D. – Park, D. H. – Cho, M. K., et al.: Feasibility and safety of a fully covered self expandable metal stent with antimigration properties for EUS-guided pancreatic duct drainage: early and midterm outcomes. *GI Endoscopy*, 2016, 93, s. 366–373.
- 19 Anderson, M. A. – Akshintala, V. – Albers, A. M., et al.: Mechanism, assessment and management of pain in chronic pancreatitis: recommendations of a multidisciplinary study group. *Pancreatology*, 2016, 16, s. 33–94.
- 20 Gurusamy, K. S. – Lusu, C. – Davidson, B. R.: Pregabalin for decreasing pain in chronic pancreatitis. *Cochrane Database Syst Rev*, 2016, 2_CDO11522.

Vliv pomocných látek na stabilitu levothyroxinu a variabilitu jeho obsahu v preparátu Euthyrox

MUDr. Mgr. Sylvie Špitálníková, Ph.D. Endokrinologická a diabetologická ambulance, Nemocnice Havlíčkův Brod, ambulance Hlinsko, Chotěboř

- 1 Agence française de sécurité sanitaire des produits de santé 2012 Commission nationale de pharmacovigilance. Zázpis z 27. 3. 2012.
- 2 FDA acts to ensure thyroid drugs don't lose potency before expiration date. 2. 10. 2007.
- 3 Gottwald-Hostalek, U. – Uhl, W. – Urgatz, B., et al.: Bioequivalence and dose proportionality of a new levothyroxine formulation that meets the 95–105% specification over the whole shelf-life: evidence from two randomized pharmacokinetic trials. ETA P3-02-06.
- 4 Gottwald-Hostalek, U. – Uhl, W. – Wolna, P., et al.: New levothyroxine formulation meeting 95–105% specification over the whole shelf-life: results from two pharmacokinetic trials. *Curr Med Res Opin*, 2017, 33, s. 169–174.
- 5 Khandelwal, D. – Tandon, N.: Overt and subclinical hypothyroidism who to treat and how. *Drugs*, 2012, 72, s. 17–33.
- 6 Medicines and Healthcare products Regulatory Agency (MHRA) 2013 Levothyroxine Tablet Products: A Review of Clinical & Quality Considerations. Dostupné z: <https://www.gov.uk/government/publications/levothyroxine-a-review-of-clinical-and-quality-considerations>, vyhledáno 3. 10. 2019.
- 7 Robertson, H. M. A. – Narayanaswamy, A. K. P. – Pereira, O., et al.: Factors contributing to high levothyroxine doses in primary hypothyroidism: an interventional audit of a large community database. *Thyroid*, 2014, 24, s. 1765–1771.
- 8 SPC přípravku Euthyrox, datum revize textu: 1. 8. 2018.
- 9 WHO expert committee on specifications for pharmaceutical preparations – WHO technical report series, No. 863 – thirty-fourth report. Dostupné z: <http://apps.who.int/medicinedocs/en/d/Js5516e/15.3.html#Js5516e.15.3>, vyhledáno 20. 3. 2017.

Aktuální možnosti léčby chronické obstrukční plicní nemoci

doc. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie 3. LF UK a Nemocnice Na Bulovce, Praha

- 1 Global Initiative for Chronic Obstructive Lung Disease: *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2019*, www.goldcopd.org.
- 2 Koblížek, V., et al.: *CHOPN – Doporučený postup ČPFS pro diagnostiku a léčbu chronické obstrukční plicní nemoci*, verze rok 2018.
- 3 Koblížek, V. – Zatloukal, J. – Konšťáček, S.: *Chronická obstrukční plicní nemoc: doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře 2019*.

Pembrolizumab v léčbě nemalobuněčného plicního karcinomu

MUDr. Marie Drösslerová Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- 1 Skříčková, J. – Kolek, V., et al.: *Základy moderní pneumoonkologie*. Maxdorf, Praha, 2017.
- 2 Imunoonkologické léky / regulační kontrolního bodu. Linkos, Česká onkologická společnost České lékařské společnosti J. E. Purkyně. Dostupné z: <https://www.linkos.cz/slovnicek/immunoonkologicke-leky-regulacni-kontrolniho-bodu/>, vyhledáno 17. 9. 2019.
- 3 Herbst, R. S. – Baas, P. – Kim, D. W., et al.: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*, 2016, 387, s. 1540–1550.
- 4 Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010). ClinicalTrials.gov Identifier: NCT01905657. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01905657>, vyhledáno 17. 9. 2019.
- 5 Reck, M. – Rodríguez-Abreu, D. – Robinson, A. G., et al.: KEYNOTE-024 Investigators: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*, 2016, 375, s. 1823–1833.
- 6 Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024). ClinicalTrials.gov. Home – ClinicalTrials.gov. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02142738>, vyhledáno 17. 9. 2019.
- 7 KEYTRUDA, 50MG INF PLV CSL 1, Státní ústav pro kontrolu léčiv. Státní ústav pro kontrolu léčiv, 2001. Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0210911&tab=texts>, vyhledáno 4. 9. 2019.

Léčba HIV – současnost a výhledy

MUDr. Svatava Snopková, Ph.D. | prof. MUDr. Petr Husa, CSc. Klinika infekčních chorob, FN a LF MU, Brno

- 1 Lu, D. Y. – Wu, H. Y. – Yarla, N. S., et al.: HAART in HIV/AIDS treatment: future trends. *Infect Disord Drug Targets*, 2018, 18, s. 15–22.
- 2 Data and statistics HIV/AIDS. World Health Organization. Dostupné z: <https://www.who.int/hiv/data/en/>, vyhledáno 30. 7. 2019.
- 3 EACS Guidelines version 9.1 – říjen 2018. Dostupné z: <http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>, vyhledáno 30. 7. 2019.
- 4 Gray, G. E. – Laher, F. – Doherty, T., et al.: Which new health technologies do we need to achieve an end to HIV/AIDS? *PLoS Biol*, 2016, 14, e1002372.
- 5 Barré-Sinoussi, F. – Abdoool Karim, S. S. – Albert, J., et al.: Expert consensus statement on the science of HIV in the context of criminal law. *J Int AIDS Soc*, 2018, 21, e25161.
- 6 Hoffmann, C.: ART 2015/2016. In: Hoffmann, C. – Rockstroh, J. K. *HIV 2015/2016*. Hamburg, Medizin Fokus Verlag, 2015, s. 64–115.
- 7 Soriano, V. – Fernandez-Montero, J. V. – Benitez-Gutierrez, L., et al.: Dual antiretroviral therapy for HIV infection. *Expert Opin Drug Saf*, 2017, 16, s. 923–932.
- 8 Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. July 10, 2019. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). Dostupné z: <https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0>, vyhledáno 30. 7. 2019.
- 9 Saag, M. S. – Benson, C. A. – Gandhi, R. T., et al.: Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. *JAMA*, 2018, 320, s. 379–396.
- 10 Mosepele, M. – Molefe-Baikai, O. J. – Grinspoon, S. K., et al.: Benefits and risks of statin therapy in the HIV-infected population. *Curr Infect Dis Rep*, 2018, 20, s. 20.
- 11 Poveda, E. – Tabernilla, A.: New insights into HIV-1 persistence in sanctuary sites during antiretroviral therapy. *AIDS Rev*, 2016, 18, s. 54–55.
- 12 Dash, P. K. – Kaminski, R. – Bella, R., et al.: Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. *Nat Commun*, 2019, 10, s. 2753.
- 13 Cary, D. C. – Peterlin, B. M.: Targeting the latent reservoir to achieve functional HIV cure. *F1000Res*, 2016, 26, s. 5.
- 14 Wong, J. K. – Yukl, S. A.: Tissue reservoirs of HIV. *Curr Opin HIV AIDS*, 2016, 11, s. 362–370.
- 15 Sengupta, S. – Siliciano, R. F.: Targeting the latent reservoir for HIV-1. *Immunity*, 2018, 48, s. 872–895.
- 16 National Institute of Allergy and Infectious Diseases (NIAID). NIH HIV experts prioritize research to achieve sustained ART-free HIV remission. National Institutes of Health (NIH) 2019. Dostupné z: <https://www.niaid.nih.gov/news-events/nih-hiv-experts-prioritize-research-achieve-sustained-art-free-hiv-remission>, vyhledáno 30. 7. 2019.
- 17 The development of HIV vaccines. In: The history of vaccines, 2019. An educational resource by the college of physicians of Philadelphia. Dostupné z: <https://www.historyofvaccines.org/content/articles/development-hiv-vaccines>, vyhledáno 30. 7. 2019.
- 18 Blackard, J. T.: HIV compartmentalization: a review on a clinically important phenomenon. *Curr HIV Res*, 2012, 10, s. 133–142.
- 19 Penton, P. K. – Blackard, J. T.: Analysis of HIV quasisppecies suggests compartmentalization in the liver. *AIDS Res Hum Retroviruses*, 2014, 30, s. 394–402.
- 20 Chun, T. W. – Eisinger, R. W. – Fauci, A. S.: Durable control of HIV infection in the absence of antiretroviral therapy. *JAMA*, 6. 6. 2019, doi: 10.1001/jama.2019.5397, epub před tiskem.
- 21 Curley, P. – Liptrott, N. J. – Owen, A.: Advances in nanomedicine drug delivery applications for HIV therapy. *Future Sci OA*, 2018, 4, FSO230.
- 22 Appay, V. – Sauce, D.: Assessing immune aging in HIV-infected patients. *Virulence*, 2017, 8, s. 529–538.
- 23 Wang, T. – Yi, R. – Green, L. A., et al.: Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat. *Cardiovasc Pathol*, 2015, 24, s. 279–282.
- 24 Seng, R. – Goujard, C. – Krastinova, E., et al.: Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy. *AIDS*, 2015, 29, s. 595–607.
- 25 Lederman, M. M. – Funderburg, N. T. – Sekaly, R. P., et al.: Residual immune dysregulation syndrome in treated HIV infection. *Adv Immunol*, 2013, 119, s. 51–83.
- 26 Wada, N. I. – Jacobson, L. P. – Margolick, J. B., et al.: The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. *AIDS*, 2015, 29, s. 463–471.
- 27 US National Institutes of Health. Therapeutic vaccine for HIV. ClinicalTrials.gov Identifier NCT01859325. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01859325>, vyhledáno 30. 7. 2019.
- 28 Vieillard, V. – Combadière, B. – Tubiana, R., et al.: HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial. *NPJ Vaccines*, 2019, 4, s. 25.
- 29 Martin, E. G. – Schackman, B. R.: Treating and preventing HIV with generic drugs-barriers in the United States. *N Engl J Med*, 2018, 378, s. 316–319.
- 30 Zhang, X.: Anti-retroviral drugs: current state and development in the next decade. *Acta Pharm Sin B*, 2018, 8, s. 131–136.
- 31 Merker, A. – Badowski, M. – Chiampas, T., et al.: Effectiveness of single- and multiple-tablet antiretroviral regimens in correctional setting for treatment-experienced HIV Patients. *J Correct Health Care*, 2018, 24, s. 52–61.
- 32 Rutsaert, S. – Steens, J. M. – Gineste, P., et al.: Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study. *J Virus Erad*, 2019, 5, s. 10–22.
- 33 Gendelman, H. E. – McMillan, J. – Bade, A. N., et al.: The promise of long-acting antiretroviral therapies: from need to manufacture. *Trends Microbiol*, 2019, 27, s. 593–606.
- 34 Patra, J. K. – Das, G. – Fraceto, L. F., et al.: Nano based drug delivery systems: recent developments and future prospects. *J Nanobiotechnol*, 2018, 16, s. 71.
- 35 Greenwood, A. D. – Ishida, Y. – O'Brien, S. P., et al.: Transmission, evolution, and endogenization: lessons learned from recent retroviral invasions. *Microbiol Mol Biol Rev*, 2018, 82, e00044-17.
- 36 Pitman, M. C. – Lau, J. S. Y. – McMahon, J. H., et al.: Barriers and strategies to achieve a cure for HIV. *Lancet HIV*, 2018, 5, s. e317–e328.
- 37 Gupta, R. K. – Abdul-Jawad, S. – McCoy, L. E., et al.: HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. *Nature*, 2019, 568, s. 244–248.

Hepatitida C – diagnóza, léčba a eliminace

MUDr. Pavel Dlouhý Infekční oddělení a HIV centrum Masarykovy nemocnice v Ústí nad Labem

- 1 World health organization. Global health sector strategy on viral hepatitis 2016–2021: to ward sending viral hepatitis. Ženeva, WHO, 2016. Dostupné z: <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?jsessionid=9212AF368D2813D91C5C5405F47D23F2?sequence=1>, vyhledáno 5. 9. 2019.
- 2 World health organization. Action plan for the health sector response to viral hepatitis in the WHO European Region. Ženeva, WHO, 2017. Dostupné z: http://www.euro.who.int/__data/assets/pdf_file/0008/357236/Hepatitis-9789289052870-eng.pdf?ua=1, vyhledáno 5. 9. 2019.
- 3 Chlibek, R. – Sosovickova, R. – Gal, P., et al.: Hepatitis C prevalence in the general adult population in the Czech Republic – results of a seroprevalence study. *PLoS One*, 2017, 12, e0175525.
- 4 Výskyt vybraných infekcí v České republice hlášených v letech 2009–2018. Praha, Státní zdravotní ústav, 2019. Dostupné z: <http://www.szu.cz/publikace/data/2018/vyskyt-vybranych-infekci-v-ceske-republice-hlasenych-v>, vyhledáno 5. 9. 2019.
- 5 Mravčík, V. – Chomynová, P. – Grohmannová, K. – Janíková, B., et al.: *Výroční zpráva o stavu ve věcech drog v České republice v roce 2017*. Praha, Úřad vlády České republiky, 2018.
- 6 Urbánek, P. – Fraňková, S. – Husa, P., et al.: Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). *Gastroent Hepatol*, 2019, 73, s. 101–125.
- 7 Hajarizadeh, B. – Cunningham, E. B. – Reid, H., et al.: Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*, 2018, 3, s. 754–767.
- 8 Suchopár, J. – Prokeš, M.: Přímé působící antivirotika proti hepatitidě typu C a jejich lékové interakce. *Remedia*, 2018, 28, s. 95–108.
- 9 Chalupa, P. – Rozsypal, H.: Pokroky a úskali v léčbě chronické HCV infekce. *Prakt Lék*, 2018, 98, s. 246–252.
- 10 Skoupá, J. – Urbánek, P.: Porovnání nákladové efektivity okamžité zahájené léčby oproti odložené terapii chronické hepatitidy C v České republice. *Gastroent Hepatol*, 2018, 72, s. 58–65.
- 11 Urbánek, P.: *Hepatitida C*. Praha, Mladá fronta, 2017.

Screening Fabryho choroby – v kardiologické ambulanci

doc. MUDr. David Zemánek, Ph.D. II. interní klinika kardiologie a angiologie VFN a 1. LF UK, Praha

- 1 Garman, S. C. – Garboczi, D. N.: The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. *J Mol Biol*, 2004, 337, s. 319.
- 2 Ortiz, A. – Germain, D. P. – Desnick, R. J., et al.: Fabry disease revisited: Management and treatment recommendations for adult patients. *Mol Genet Metab*, 2018, 123, s. 416–427.
- 3 Moon, J. C. – Sachdev, B. – Elkington, A. G., et al.: Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. *Eur Heart J*, 2003, 24, s. 2151.
- 4 Sheppard, M. N.: The heart in Fabry's disease. *Cardiovasc Pathol*, 2011, 20, s. 8–14.
- 5 Krämer, J. – Weidemann, F.: Biomarkers for diagnosing and staging of Fabry disease. *Curr Med Chem*, 2018, 25, s. 1530–1537.
- 6 Nakao, S. – Takenaka, T. – Maeda, M., et al.: An atypical variant of Fabry's disease in men with left ventricular hypertrophy. *N Engl J Med*, 1995, 333, s. 288–293.
- 7 Paleček, T. – Honzíkova, J. – Poupetova, H., et al.: Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). *J Inherit Metab Dis*, 2014, 37, s. 455–460.
- 8 Monserrat, L. – Gimeno-Blanes, J. R. – Marín, F., et al.: Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol*, 2007, 50, s. 2399–2403.
- 9 Elliott, P. – Baker, R. – Pasquale, F., et al.: ACES study group: Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. *Heart*, 2011, 97, s. 1957–1960.

Pacientka s Gaucherovou nemocí

MUDr. Hana Ptoszková Klinika dětského lékařství FN Ostrava

- 1 Honzík, T. – Zeman, J.: *Dědičné poruchy metabolismu v kazuistikách*, 2016, Mladá fronta, Praha, s. 260.
- 2 Kulhánek, J. – Malinová, V. – Honzík, T. – Magner, M.: Enzymová substituční terapie u lysosomálních onemocnění. *Československá pediatrie*, 2015, 70, s. 224–231.
- 3 Malinová, V. – Mazurová, S. – Dvořáková, L.: Gaucherova nemoc a lysosomální onemocnění – současné možnosti diagnostiky a léčby. *Remedia*, 2016, 26, s. 268–276.
- 4 Ion: Splenomegalie vždy něco znamená – třeba Gaucherovu nemoc, *Medical Tribune*, 2016, 12, s. C1–C2.
- 5 Malinová V.: Morbus Gaucher: Vzácná onemocnění. *Solen*, 2013, s. 6–21.
- 6 Dandana, A. – Ben Khelifa, S. – Chahed, H., et al.: Gaucher disease: clinical, biological and therapeutic aspects. *Pathobiology*, 2016, 83, s. 13–23.
- 7 Thomas, A. S. – Mehta, A. – Hughes, D. A., et al.: Gaucher disease: haematological presentations and complications. *Br J Haematol*, 2014, 165, s. 427–440.